Navigation Links
Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
Date:5/22/2012

Officer.  "CLP1001 could ultimately be used alongside standard medications to improve the physical functionality and overall quality of life of these heart failure patients."

About the Phase 2a Study
The double-blind, randomized, parallel, placebo-controlled study examined the effect of CLP1001 over eight weeks in 111 heart failure patients with chronic kidney disease (CKD). 

CLP1001-treated patients achieved significantly greater weight loss – an accepted measurement of fluid retention – as compared to placebo over the first two weeks of treatment.  This trend continued through the end of the study.  After eight weeks of treatment, a greater number of patients experienced marked or moderately improved breathing in the CLP1001 group and the average distance walked in the 6-Minute Walk Test was larger in patients receiving CLP1001 versus the placebo population.  CLP1001 improved functional heart capacity as assessed by the New York Heart Association (NYHA) classification by at least one class compared to the placebo group (48.8% vs. 17.4%; p=0.002).  Similar results favoring the CLP1001 group were seen when examining quality of life.

These data were presented by Dr. Costanzo during the Late-Breaking Trials 2 Special Session at the ESC Heart Failure Congress in a talk titled "A Double-Blind, Randomized, Parallel, Placebo Controlled Study Examining the Effect of Cross-linked Polyelectrolyte (CLP) in Heart Failure Patients with Chronic Kidney Disease – Sorbent  CTST-21." 

About Heart Failure
Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs.  Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older.  Hea
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Allied Healthcare Announces Litholyme(TM) -- New CO2 Absorbent Used in Anesthesia
2. Reportlinker Adds US Enzyme-Linked Immunosorbent Assay (ELISA) Industry
3. Sorbent Therapeutics Completes $36 Million Series B Financing for Net of $53 Million
4. CytoSorbents Corporation to Exhibit at the Advanced Technology Applications for Combat Casualty Care Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014   Decision Resources Group finds ... anemic chronic kidney disease non-dialysis (CKD-ND) patients are ... medication. In addition, one-year persistency is similar between ... Other key findings from the report entitled ... Erythropoiesis Stimulating Agents in Late Stage Chronic Kidney ...
(Date:9/30/2014)... SAN DIEGO , 30. September ... Logo - http://photos.prnewswire.com/prnh/20130430/LA01948LOGO ... ein Medizintechnikunternehmen, das ein minimal-invasives 3D-Herzkammer-Bildgebungs- ... der Ursachen entwickelt, die zu komplexen ... aufrechterhalten, hat den Abschluss einer zusätzlichen ...
(Date:9/30/2014)... DIEGO , Sept. 30, 2014   ... developing a minimally invasive real-time 3D Cardiac Chamber Imaging ... that cause and / or sustain complex cardiac arrhythmias, ... $26.2M financing to continue developing its imaging/mapping system as ... The financing will allow Acutus Medical to complete work ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3
... Water Street Healthcare Partners , a strategic private equity ... it has acquired MarketLab, Inc.  Water Street,s ... specialty healthcare distribution sector.  The acquisition expands Water Street,s ... life sciences, medical devices and services to 13. ...
... -- Dehaier Medical Systems Ltd. (NASDAQ: ... in the development, assembly, marketing and sale of medical ... that it was granted three new patents by State ... ("SIPO"). The patent awards were related to the design ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- There,s no genetic ... type 2 diabetes, a new study says. Some ... D might protect people against type 2 diabetes, raising ... and the blood sugar disease. In this study, ... vitamin D by focusing on genes that control blood ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- Children conceived either ... the birth of a sibling could be at increased risk ... study,s lead author and an outside expert agree that the ... in autism. "Most importantly, it is important that parents ... even when pregnancies are close together or far apart," said ...
(Date:9/30/2014)... Power plant standards to cut climate-changing carbon emissions ... substantial human health benefits, according to a new ... on the policy options included in the final ... prevent thousands of premature deaths and hospitalizations, and ... every year., In the new study, Health Co-benefits ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... breast cancer is the leading cause of cancer death ... why so many medical professionals encourage women to get ... only a minority of suspicious mammograms actually leads to ... needless worry for women and their familiesnot to mention ... ultrasounds and biopsies. , Recently, a different type ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2
... I-Therapeutix, Inc. announced today that Mr. Richard Packard ... Unit, King Edward VII Hospital, Windsor, UK, performed the ... Mark approved I-ZIP(R) Adherent Ocular Bandage. All phacoemulsification ... Packard. Patients received a foldable IOL with wound-assisted ...
... to Benefit the IP - Over $2,200 In ... Donald Verger, award-winning photographer and philanthropist is taking ... it to help raise awareness for the nonprofit ... deeply grateful to Mr. Verger for using his ...
... 3 Zimmer Holdings, Inc. (NYSE: ZMH ; ... earnings conference call will be broadcast live over the Internet ... A news release detailing the quarterly results will be ... call.The live audio webcast can be accessed via Zimmer,s Investor ...
... save brain cells from ravages of neurodegenerative disease , , ... they,ve found a possible way to prevent brain cells ... , The work is still in the preliminary stages, ... work in humans. Still, a Huntington,s disease expert said ...
... ,s award-winning document management suite recommended for ... and human resourcesCLEVELAND, April 3 It,s no secret. ... at the right time allows for better patient care. ... is they don,t yet have the tools to operate ...
... When the need for speed is critical, how can ... sending alerts to help prevent or stop a public ... be notified about disease outbreaks, illness from food borne ... Researchers from the Regenstrief Institute, Inc. in collaboration with ...
Cached Medicine News:Health News:I-Therapeutix Announces First Commercial Use of I-ZIP(R) Adherent Ocular Bandage for Clear Corneal Cataract Incisions 2Health News:Acclaimed New England Photographer Donald Verger Holds 'Faces of Innocence' Charity Event for the Innocence Project 2Health News:Scientists Uncover New Weapon Against Huntington's 2Health News:American Hospital Association Expands OnBase Endorsement to All Hospital Departments 2Health News:American Hospital Association Expands OnBase Endorsement to All Hospital Departments 3Health News:American Hospital Association Expands OnBase Endorsement to All Hospital Departments 4Health News:Getting the word out when the need for speed is critical to public health 2Health News:Getting the word out when the need for speed is critical to public health 3
The DSL-05-01-MEM Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Measles virus in human serum. This assay is intended fo...
... determines osmolality at room temperature with the ... get are cryoscopic artifacts due to high ... interfere with freezing point determinations. The superbly ... Vapro osmometer has a much broader range ...
Rapid assay, results in 1 hours,Range 20-800 ng/mL; sensitivity 2.5 ng/mL,Can be used for animal sera; requires extraction protocol and steroid free serum...
... IMMULITE 2000 assays ... with the IMMULITE 2000, ... access immunoassay analyzer. IMMULITE ... through centralization, and a ...
Medicine Products: